StockNews.com initiated coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Free Report) (TSE:AEZ) in a research report released on Monday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Price Performance
AEZS stock opened at $1.95 on Monday. The stock has a market cap of $9.48 million, a PE ratio of -0.57 and a beta of 1.57. The firm’s 50-day simple moving average is $1.97 and its 200 day simple moving average is $1.89. Aeterna Zentaris has a fifty-two week low of $1.36 and a fifty-two week high of $3.38.
Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) last released its earnings results on Wednesday, March 27th. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.19). The company had revenue of $0.12 million for the quarter. Aeterna Zentaris had a negative net margin of 368.01% and a negative return on equity of 63.20%.
Aeterna Zentaris Company Profile
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.
Read More
- Five stocks we like better than Aeterna Zentaris
- Financial Services Stocks Investing
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- The Significance of Brokerage Rankings in Stock Selection
- Merger or Not, Albertson’s Companies is a Good Buy
- How to Choose Top Rated Stocks
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.